Drugs / Abagovomab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00058435 | Dec 2002 → Mar 2004 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00103545 | Jul 2003 → Aug 2004 | fallopian tube neoplasm, ovarian cancer, peritoneal neoplasm | AGO Study Group | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00418574 | Dec 2006 → Dec 2010 | ovarian carcinoma | Menarini Group | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-06-06 | Menarini Group | Results The mimosa study: expectations blighted, sense of pride remains high menarini.com ↗
Even if the treatment itself has been well tolerated, the vaccinations carried out using Abagovomab did not confirm the expected levels of benefit foreseen during the initial studies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-06-06 | Menarini Group | The mimosa study: expectations blighted, sense of pride remains high menarini.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abagovomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00058435 ↗ |
| Known as | ACA 125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103545 ↗ |
| Known as | MEN-2234 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742981 ↗ |
| Modality | Monoclonal antibody | “substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovomab trial (NCT00418574).” PMID 24952307 ↗ Jun 2014 |
| Route | Intramuscular | “intramuscularly (IM)” NCT00058435 ↗ |
| Target | MUC16 | “Mucin-16 other” CHEMBL1742981 ↗ |